Blue Shield of California Slashes Humira Biosimilar Prices in Landmark Deal
Blue Shield of California Slashes Humira Biosimilar Prices in Landmark Deal
However, it has faced criticism for its high pricing and extended market exclusivity, which ended in January 2023.Blue Shield of California is shaking up the pharmacy landscape with a landmark deal to drastically reduce the price of a biosimilar alternative to AbbVie Inc.'s (NYSE:ABBV) Humira, one of the world's most expensive and widely used drugs.
加州藍盾公司通過一項具有突破意義的交易，徹底降低了亞馬遜公司（紐交所：ABBV）旗下荷蘭美拉（Humira）生物類似物的價格，從而改變了藥店的景觀，這是全球價格最昂貴且使用最廣泛的藥物之一。
Humira, approved by the FDA in 2002, has long dominated the market, treating conditions like arthritis and Crohn's disease.
艾伯維公司的阿瑞士藥物Humira獲得FDA批准於2002年，長期佔據市場主宰地位，用於治療關節炎和克羅恩病等疾病。
Also Read: AbbVie's Arthritis Drug Humira Retains Market Dominance Despite Biosimilar Competition, Challenges Biosimilar Industry Viability.
閱讀更多：儘管面臨生物類似物競爭和挑戰，艾伯維公司的關節炎藥物Humira仍然保持市場主導地位，挑戰生物類似物行業的生存能力。
However, it has faced criticism for its high pricing and extended market exclusivity, which ended in January 2023.
然而，該藥物由於定價過高和市場獨佔權的延長而受到批評，這一獨佔權於2023年1月結束。
Blue Shield, which processes around 40,000 Humira prescriptions annually, spends more on the drug than any other medication for its members, making this price-cutting move both timely and essential for addressing the rising cost of healthcare.
藍盾公司每年處理約40,000份Humira處方，爲其會員花費在該藥物上的金額超過其他任何藥物，因此，這一降價舉措及時且十分必要，以應對醫療成本上漲。
The nonprofit health plan announced that it would purchase Fresenius Kabi's FDA-approved biosimilar adalimumab-aacf at a net price of $525 per monthly dose, a significant reduction from Humira's market-reported price of $2,100.
非營利性健康計劃宣佈將以每月$525的淨價格購買Fresenius Kabi的FDA批准的生物類似物阿達利單抗-aacf，這比Humira市場報價的$2,100低得多。
The deal, facilitated by Evio Pharmacy Solutions, aims to eliminate excessive markups typically imposed by pharmacy benefit managers (PBMs) in the current drug supply chain.
由Evio藥店解決方案推動的交易旨在消除目前藥物供應鏈中通常由藥店利潤管理人員（PBMs）強加的過高加價。
The new pricing model is part of Blue Shield's Pharmacy Care Reimagined initiative, which rethinks traditional PBM structures to ensure more transparent and affordable pricing.
新的定價模式是藍盾公司「藥房護理重塑」計劃的一部分，重新思考傳統的PBm結構，以確保更透明和負擔得起的定價。
The aligned incentives and simplified supply chain have enabled Blue Shield to provide Fresenius Kabi's biosimilar to its members. Starting in January 2025, most commercial members are expected to pay $0 out of pocket.
通過獎勵措施和簡化供應鏈，Blue Shield得以向其會員提供Fresenius Kabi的生物類似藥品。預計從2025年1月開始，大多數商業會員將不需支付任何費用。
This move sets a critical precedent as the pharmaceutical industry approaches a "biosimilar cliff," with more low-cost alternatives entering the market.
這一舉動爲藥品行業在接近"生物類似藥品懸崖"時樹立了關鍵的先例，更多低成本替代品進入市場。
Last month, UnitedHealth Group Inc. (NYSE:UNH) said it would remove Humira from some of its preferred reimbursement lists starting January 1, 2025. The company will recommend lower-cost biosimilar versions instead.
上個月，UnitedHealth Group Inc.（紐交所：UNH）表示將於2025年1月1日起從部分首選報銷名單中移除Humira。該公司將推薦更低成本的生物類似藥品版本。
Price Action: ABBV stock is down 0.45% at $195.93 at the last check on Thursday.
股價走勢：艾伯維公司股票在週四最後交易時下跌0.45%，報195.93美元。
- Amazon's Profitable Essential Merchandise, Efficiency Gains Set To Drive Growth: Analyst
- 亞馬遜盈利的基本商品，效率提升有望推動增長：分析師
Photo via Wikimedia Commons
照片通過Wikimedia Commons
譯文內容由第三人軟體翻譯。